Hemastatx develops transformative therapies for severe bleeding disorders. Its lead program, HMX001, is a first-in-class antibody therapy for von Willebrand Factor-related disorders.
Hemastatx
Resident at Main Campus
I was really impressed by the vibe on campus; the modern look, state-of-the-art infrastructure, impressive biotech community, and proximity to big pharma make it a unique place.
Hemastatx
